Xeris Pharmaceuticals(DE:2B30)
€14.90+0.06 (+0.40%)
DE:2B30
Xeris Pharmaceuticals stock drug pipeline
€14.90
At close:+0.06 (+0.40%)
Xeris Pharmaceuticals (2B30) Drug Pipeline
0 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Levothyroxine Sodium | Hypothyroidism | Phase II | Completed | Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism | Mar 28, 2023 | ― |
| Pram9, Regular Insulin + Pramlintide, Regular Insulin | Diabetes Mellitus, Type 1, Insulin-Dependent Diabetes Mellitus | Phase II | Completed | Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D | Aug 28, 2019 | ― |
| Glucagon Rtu Injection With Insulin Pump Reduction, Vehicle For Glucagon Rtu Injection With Insulin Pump Reduction, Glugaon Rtu Injection Without Insulin Pump Reduction | Hypoglycemia | Phase II | Completed | Glucagon Ready-to-Use (RTU) for Prevention of Exercise-Induced Hypoglycemia During Aerobic Exercise in Adults With T1D | Feb 12, 2019 | ― |
| Glucagon Rtu | Hyperinsulinemic Hypoglycemia | Phase II | Completed | Glucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric Surgery | Dec 07, 2018 | ― |
| G-Pen, Novo Glucagon | Type 1 Diabetes Mellitus, Insulin Hypoglycemia, Severe Hypoglycemia | Phase III | Completed | G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes | Nov 08, 2018 | ― |
| Glucagon | Diabetes Mellitus, Type 1, Hypoglycemia Unawareness | Phase II | Terminated | Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses | Mar 25, 2018 | ― |
| G-Pen, Lilly Glucagon | Type 1 Diabetes Mellitus, Insulin Hypoglycemia, Severe Hypoglycemia | Phase III | Completed | G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes | Feb 13, 2018 | ― |
| Glucagon | Diabetes Mellitus, Type 1 | Phase III | Completed | Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients | Mar 16, 2017 | ― |
| Glucagon | Congenital Hyperinsulinism | Phase II | Completed | CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism | Oct 14, 2016 | ― |
| G-Pump™ (Glucagon Infusion) | Hypoglycemia, Complications Of Bariatric Procedures | Phase II | Completed | Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients | Mar 30, 2016 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Levothyroxine Sodium | Phase II | Hypothyroidism | Completed | Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism | Mar 28, 2023 | ― |
| Pram9, Regular Insulin + Pramlintide, Regular Insulin | Phase II | Diabetes Mellitus, Type 1, Insulin-Dependent Diabetes Mellitus | Completed | Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D | Aug 28, 2019 | ― |
| Glucagon Rtu Injection With Insulin Pump Reduction, Vehicle For Glucagon Rtu Injection With Insulin Pump Reduction, Glugaon Rtu Injection Without Insulin Pump Reduction | Phase II | Hypoglycemia | Completed | Glucagon Ready-to-Use (RTU) for Prevention of Exercise-Induced Hypoglycemia During Aerobic Exercise in Adults With T1D | Feb 12, 2019 | ― |
| Glucagon Rtu | Phase II | Hyperinsulinemic Hypoglycemia | Completed | Glucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric Surgery | Dec 07, 2018 | ― |
| G-Pen, Novo Glucagon | Phase III | Type 1 Diabetes Mellitus, Insulin Hypoglycemia, Severe Hypoglycemia | Completed | G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes | Nov 08, 2018 | ― |
| Glucagon | Phase II | Diabetes Mellitus, Type 1, Hypoglycemia Unawareness | Terminated | Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses | Mar 25, 2018 | ― |
| G-Pen, Lilly Glucagon | Phase III | Type 1 Diabetes Mellitus, Insulin Hypoglycemia, Severe Hypoglycemia | Completed | G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes | Feb 13, 2018 | ― |
| Glucagon | Phase III | Diabetes Mellitus, Type 1 | Completed | Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients | Mar 16, 2017 | ― |
| Glucagon | Phase II | Congenital Hyperinsulinism | Completed | CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism | Oct 14, 2016 | ― |
| G-Pump™ (Glucagon Infusion) | Phase II | Hypoglycemia, Complications Of Bariatric Procedures | Completed | Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients | Mar 30, 2016 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Xeris Pharmaceuticals (DE:2B30) have in its pipeline
Xeris Pharmaceuticals DE:2B30 is currently developing the following drugs: Levothyroxine Sodium, Pram9, Regular Insulin + Pramlintide, Regular Insulin, Glucagon Rtu Injection With Insulin Pump Reduction, Vehicle For Glucagon Rtu Injection With Insulin Pump Reduction, Glugaon Rtu Injection Without Insulin Pump Reduction, Glucagon Rtu, G-Pen, Novo Glucagon, Glucagon, G-Pen, Lilly Glucagon, G-Pump™ (Glucagon Infusion), G-Pen (Glucagon Injection), Lilly Glucagon (Glucagon Injection [Rdna Origin]), Novo Nordisk Glucagen®, G-Pump™ (Glucagon Infusion), G-Pen Mini™ (Glucagon Injection), G-Pen(Tm) 1 Mg, Lilly Glucagon(Tm) 1 Mg, G-Pen(Tm) 0.5 Mg. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

